Adamis Announces Results of 2021 Annual Meeting of Stockholders
July 19 2021 - 04:05PM
Business Wire
Based on Results Provided by the Inspector
of Election, Stockholders Re-Elected All Five Members of the
Company's Board of Directors
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or
the “Company”) today announced that based on the Inspector of
Election’s certified results from the Company’s 2021 Annual Meeting
of Stockholders (the “Annual Meeting”), each of the Company’s
nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo,
Ph.D., David J. Marguglio and Richard C. Williams – have been
re-elected to the Board of Directors (the "Board"). According to
the Inspector of Election’s report, stockholders approved all other
proposals considered at the Annual Meeting, including the approval
on an advisory basis of the compensation paid to named executive
officers and the ratification on an advisory basis of the
appointment of our registered public accounting firm BDO USA, LLP
for 2021. The Board thanks the Adamis stockholders for their
engagement and support.
About Adamis
Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. Adamis’ naloxone injection
product candidate, ZIMHI, for the treatment of opioid overdose is
currently under FDA review. Adamis is developing additional
products, including treatments for acute respiratory diseases, such
as COVID-19, and radiation dermatitis. The company’s subsidiary, US
Compounding Inc. (“USC”), compounds sterile prescription drugs, and
certain nonsterile drugs for human and veterinary use by hospitals,
clinics, surgery centers, and vet clinics throughout most of the
United States. For additional information about Adamis
Pharmaceuticals, please visit www.adamispharmaceuticals.com.
Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those that express
plans, anticipation, intent, contingencies, goals, targets or
future development and/or otherwise are not statements of
historical fact. These statements relate to future events or future
results of operations, including, but not limited to the following
statements: the Company’s beliefs concerning the safety and
effectiveness of its products and product candidates; the Company’s
ability to successfully commercialize the products and product
candidates described in this press release, itself or through
commercialization partners, and the Company’s beliefs concerning
the commercial success of its products; and other statements
concerning our future operations, activities and financial results.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, which may cause Adamis’
actual results to be materially different from the results
anticipated by such forward-looking statements. We cannot assess
the impact of each factor on our business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. You should not place undue reliance on any
forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made, and except as may
be required by applicable law, we undertake no obligation to update
or release publicly the results of any revisions to these
forward-looking statements or to reflect events or circumstances
arising after the date of this press release. Certain of these
risks and additional risks, uncertainties, and other factors are
described in greater detail in Adamis’ filings from time to time
with the SEC, including its annual report on Form 10-K for the year
ended December 31, 2020 and subsequent filings with the SEC, which
Adamis strongly urges you to read and consider, all of which are
available free of charge on the SEC's web site at
http://www.sec.gov.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210719005770/en/
Saratoga Proxy Consulting John Ferguson / Ann Marie Mellone,
212-257-1311 jferguson@saratogaproxy.com /
amellone@saratogaproxy.com MKA Greg Marose, 646-386-0091
gmarose@mkacomms.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2023 to Mar 2024